An innovative combination of cypropheptadine and prazosin for the treatment of alcohol use disorder: a double-blind, randomised, parallel-group, three-arm, multicentre, placebo-controlled phase 2 trial

INTRODUCTION: Animal studies have shown that the simultaneous blockade of α1b-noradrenergic receptors and 5HT2A-serotonergic receptors strongly decreases alcohol intake. In addition, recent clinical studies have indicated that the selective α1b antagonist prazosin could be effective on alcohol use r...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubin, H.-J., Puech, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567187/
http://dx.doi.org/10.1192/j.eurpsy.2022.346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567187/
http://dx.doi.org/10.1192/j.eurpsy.2022.346

Ejemplares similares